![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » ENZON PHARMACEUTICALS, INC. AND SANTARIS PHARMA A/S ENTER INTO GLOBAL COLLABORATION TO DEVELOP NOVEL CANCER THERAPEUTICS
ENZON PHARMACEUTICALS, INC. AND SANTARIS PHARMA A/S ENTER INTO GLOBAL COLLABORATION TO DEVELOP NOVEL CANCER THERAPEUTICS
July 27, 2006
Enzon Pharmaceuticals, Inc. and Santaris Pharma A/S announced that the companies have entered into a collaboration to co-develop and commercialize a series of innovative RNA Antagonists based on Santaris Pharma's LNA (locked nucleic acid) technology and utilizing Enzon's oncology drug development expertise. BioSpace (http://www.biospace.com/news_story.aspx?StoryID=25481&full=1)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct